Evensen S A, Stavem P
Acta Med Scand. 1986;219(1):79-83.
An intermittent combination chemotherapy program was initiated in 1971-79 in 172 patients, aged 15-59 years, with acute leukemia (131 myelogenous (AML) and 41 lymphoblastic (ALL]. Sixteen patients with AML and 6 with ALL have survived for more than 5 years. These long-term survivors represent 24% of AML and 18% of ALL patients who obtained complete remission. Twelve patients (10 AML and 2 ALL) are in continuous first remission 5.5-13.5 years after diagnosis. Occasional late relapses up to 9 years after diagnosis make it impossible to declare any individual patient cured.
1971年至1979年，针对172名年龄在15至59岁之间的急性白血病患者（131例为髓性白血病（AML），41例为淋巴细胞白血病（ALL））启动了间歇联合化疗方案。16例AML患者和6例ALL患者存活超过5年。这些长期存活者分别占获得完全缓解的AML患者的24%和ALL患者的18%。12例患者（10例AML和2例ALL）在诊断后5.5至13.5年处于持续首次缓解状态。诊断后长达9年偶尔出现的晚期复发使得无法宣布任何个体患者治愈。
